Larimar Therapeutics Advances Nomlabofusp Toward FDA Approval with Breakthrough Designation — Larimar Therapeutics, Inc.

Event summary

FDA granted Breakthrough Therapy Designation to nomlabofusp for treating Friedreich’s ataxia (FA) in February 2026.
Topline open label study data supporting BLA submission expected in Q2 2026.
Global Phase 3 confirmatory study screening to begin in Q2 2026, with first patient dosing mid-2026.
$115 million public offering closed in February 2026, extending cash runway into Q2 2027.

The big picture

Larimar Therapeutics is making significant strides in advancing nomlabofusp, a potential first disease-modifying therapy for Friedreich’s ataxia. The Breakthrough Therapy Designation and ongoing FDA alignment highlight the urgency to address this rare disease. With a strengthened balance sheet from its recent financing, Larimar is well-positioned to execute on its registrational milestones over the next year.

What we're watching

Regulatory Alignment: Whether FDA’s continued alignment on BLA content will smooth the path to accelerated approval for nomlabofusp.
Clinical Execution: The pace at which Larimar can initiate and complete its global Phase 3 study, critical for confirming nomlabofusp’s efficacy.
Financial Sustainability: How effectively Larimar manages its increased R&D expenses while maintaining its extended cash runway into Q2 2027.